Cargando…

How Is Vaccine Effectiveness Scaled by the Transmission Dynamics of Interacting Pathogen Strains with Cross-Protective Immunity?

BACKGROUND: Many novel vaccines can cover only a fraction of all antigenic types of a pathogen. Vaccine effectiveness (VE) in the presence of interactions between vaccine strains and others is complicated by the interacting transmission dynamics among all strains. The present study investigated how...

Descripción completa

Detalles Bibliográficos
Autores principales: Omori, Ryosuke, Cowling, Benjamin J., Nishiura, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511363/
https://www.ncbi.nlm.nih.gov/pubmed/23226374
http://dx.doi.org/10.1371/journal.pone.0050751
_version_ 1782251591246544896
author Omori, Ryosuke
Cowling, Benjamin J.
Nishiura, Hiroshi
author_facet Omori, Ryosuke
Cowling, Benjamin J.
Nishiura, Hiroshi
author_sort Omori, Ryosuke
collection PubMed
description BACKGROUND: Many novel vaccines can cover only a fraction of all antigenic types of a pathogen. Vaccine effectiveness (VE) in the presence of interactions between vaccine strains and others is complicated by the interacting transmission dynamics among all strains. The present study investigated how the VE estimates measured in the field, based on estimated odds ratio or relative risks, are scaled by vaccination coverage and the transmission dynamics in the presence of cross-protective immunity between two strains, i.e. vaccine and non-vaccine strains. METHODOLOGY/PRINCIPAL FINDINGS: Two different types of epidemiological models, i.e. with and without re-infection by the same antigenic type, were investigated. We computed the relative risk of infection and the odds ratio of vaccination, the latter of which has been measured by indirect cohort method as applied to vaccine effectiveness study of Streptococcus pneumoniae. The VE based on the relative risk was less sensitive to epidemiological dynamics such as cross-protective immunity and vaccination coverage than the VE calculated from the odds ratio, and this was especially the case for the model without re-infection. Vaccine-induced (cross-protective) immunity against a non-vaccine strain appeared to yield the highest impact on the VE estimate calculated from the odds ratio of vaccination. CONCLUSION: It is essential to understand the transmission dynamics of non-vaccine strains so that epidemiological methods can appropriately measure both the direct and indirect population impact of vaccination. For pathogens with interacting antigenic types, the most valid estimates of VE, that are unlikely to be biased by the transmission dynamics, may be obtained from longitudinal prospective studies that permit estimation of the VE based on the relative risk of infection among vaccinated compared to unvaccinated individuals.
format Online
Article
Text
id pubmed-3511363
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35113632012-12-05 How Is Vaccine Effectiveness Scaled by the Transmission Dynamics of Interacting Pathogen Strains with Cross-Protective Immunity? Omori, Ryosuke Cowling, Benjamin J. Nishiura, Hiroshi PLoS One Research Article BACKGROUND: Many novel vaccines can cover only a fraction of all antigenic types of a pathogen. Vaccine effectiveness (VE) in the presence of interactions between vaccine strains and others is complicated by the interacting transmission dynamics among all strains. The present study investigated how the VE estimates measured in the field, based on estimated odds ratio or relative risks, are scaled by vaccination coverage and the transmission dynamics in the presence of cross-protective immunity between two strains, i.e. vaccine and non-vaccine strains. METHODOLOGY/PRINCIPAL FINDINGS: Two different types of epidemiological models, i.e. with and without re-infection by the same antigenic type, were investigated. We computed the relative risk of infection and the odds ratio of vaccination, the latter of which has been measured by indirect cohort method as applied to vaccine effectiveness study of Streptococcus pneumoniae. The VE based on the relative risk was less sensitive to epidemiological dynamics such as cross-protective immunity and vaccination coverage than the VE calculated from the odds ratio, and this was especially the case for the model without re-infection. Vaccine-induced (cross-protective) immunity against a non-vaccine strain appeared to yield the highest impact on the VE estimate calculated from the odds ratio of vaccination. CONCLUSION: It is essential to understand the transmission dynamics of non-vaccine strains so that epidemiological methods can appropriately measure both the direct and indirect population impact of vaccination. For pathogens with interacting antigenic types, the most valid estimates of VE, that are unlikely to be biased by the transmission dynamics, may be obtained from longitudinal prospective studies that permit estimation of the VE based on the relative risk of infection among vaccinated compared to unvaccinated individuals. Public Library of Science 2012-11-30 /pmc/articles/PMC3511363/ /pubmed/23226374 http://dx.doi.org/10.1371/journal.pone.0050751 Text en © 2012 Omori et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Omori, Ryosuke
Cowling, Benjamin J.
Nishiura, Hiroshi
How Is Vaccine Effectiveness Scaled by the Transmission Dynamics of Interacting Pathogen Strains with Cross-Protective Immunity?
title How Is Vaccine Effectiveness Scaled by the Transmission Dynamics of Interacting Pathogen Strains with Cross-Protective Immunity?
title_full How Is Vaccine Effectiveness Scaled by the Transmission Dynamics of Interacting Pathogen Strains with Cross-Protective Immunity?
title_fullStr How Is Vaccine Effectiveness Scaled by the Transmission Dynamics of Interacting Pathogen Strains with Cross-Protective Immunity?
title_full_unstemmed How Is Vaccine Effectiveness Scaled by the Transmission Dynamics of Interacting Pathogen Strains with Cross-Protective Immunity?
title_short How Is Vaccine Effectiveness Scaled by the Transmission Dynamics of Interacting Pathogen Strains with Cross-Protective Immunity?
title_sort how is vaccine effectiveness scaled by the transmission dynamics of interacting pathogen strains with cross-protective immunity?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511363/
https://www.ncbi.nlm.nih.gov/pubmed/23226374
http://dx.doi.org/10.1371/journal.pone.0050751
work_keys_str_mv AT omoriryosuke howisvaccineeffectivenessscaledbythetransmissiondynamicsofinteractingpathogenstrainswithcrossprotectiveimmunity
AT cowlingbenjaminj howisvaccineeffectivenessscaledbythetransmissiondynamicsofinteractingpathogenstrainswithcrossprotectiveimmunity
AT nishiurahiroshi howisvaccineeffectivenessscaledbythetransmissiondynamicsofinteractingpathogenstrainswithcrossprotectiveimmunity